The approval means that Libtayo is now the first immunotherapy approved in Europe to treat advanced cervical cancer, regardless of PD-L1 expression or tumour histology. The fourth leading cause of ...

That means Libtayo has a chance to build a position as a go-to immunotherapy in cervical cancer, which is the fourth most commonly occurring cancer in women with around 500,000 cases worldwide ...

The PD-L1 IHC 22C3 PharmDx (Code SK006) assay is now certified for use to aid treatment decisions for patients with gastric or gastroesophageal junction adenocarcinoma.